Thomas D Wang, MD, PhD

I am an ABIM board-certified gastroenterologist with broad scientific training in biology, biomedical engineering, and electrical engineering. I use my broad, multi-disciplinary expertise to bridge unmet needs in clinical medicine with technological innovations in engineering. As a physician, I use my access to the clinic to accelerate translation of discoveries found in the lab. My team has pioneered the clinical use of monomer peptides as targeted imaging agents to detect epithelia dysplasia. My lab has expertise in the development of peptide ligands that bind specifically to cell surface targets overexpressed in early-stage cancers. We have previously identified and validated peptides specific for EGFR, ErbB2, claudin-1, FGFR2, c-Met, Prdx1, GPC3, CD44, and EpCAM using phage display methods and structural models. We are expert at arranging peptides in multimer configurations to enhance multivalent binding interactions for increased sensitivity, specificity, and affinity. I have served as the PI for a number of NIH-funded research programs, including 1) Network for Translational Research (NTR), 2) Barrett’s Esophagus Translational Research Network (BETRNet), and 3) Bioengineering Research Partnership (BRP).
Fellowship – Stanford University School of Medicine, Gastroenterology
Residency – Boston University School of Medicine, Internal Medicine
Graduate School – MIT (PhD)
Medical School – Harvard Medical School (MD)

Specialty
Gastroenterology, Internal Medicine

Area of practice
General gastroenterology, gastroesophageal reflux, Barrett's esophagus, irritable bowel syndrome, colon cancer screening

Research
Molecular imaging of gastrointestinal diseases, development of molecular probes to target detection of pre-cancerous lesions, novel optical imaging instrumentation for high resolution imaging, advance endoscopic imaging, and intra-vital microscopy